Drugs / PBT2
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02249728 | Jun → Jul 2014 | — | Prana Biotechnology Limited | Completed | No outcome recorded |
| Phase 1 | NCT02107313 | May → Jun 2014 | — | Prana Biotechnology Limited | Completed | No outcome recorded |
| Phase 1 | NCT02109497 | May → Jun 2014 | — | Prana Biotechnology Limited | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01590888 | Apr 2012 → Jul 2013 | Huntington disease | Prana Biotechnology Limited | Completed | No outcome recorded |
| Phase 2 | NCT00471211 | Dec 2006 → Dec 2007 | Alzheimer disease | Prana Biotechnology Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PBT2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00471211 ↗ |
| Modality | Small molecule | “PBT2 is a metal-protein attenuating compound (MPAC)” PMID 18672400 ↗ Jul 2008 |
| Route | Oral | “250mg capsules administered orally once per day for 26 weeks” NCT01590888 ↗ |